[EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
申请人:ABBOTT LAB
公开号:WO2003070247A1
公开(公告)日:2003-08-28
Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
申请人:——
公开号:US20040209884A1
公开(公告)日:2004-10-21
Compounds of formula (I)
1
are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
Compounds of formula (I)
are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.